Here's yet another example of why big pharma can't do biotech - they keep sacking the scientists needed to develop drugs. I've lost count of the amount of times we see this.
No surprise if we see Merck in a couple of years offloading remaining Cubist IP & programs they couldn't take further, for a biotech to buy cheaply, take it up to PIII then sell value added back to Merck.
Merck's CEO is a lawyer, not an ex soft drink Co. boss. Either way, still not much use to say a brilliant young upcoming biotech scientist looking for some mentorship as he/she goes about developing breakthrough medical drugs.